āagmanLoginNot investment advice. Data and computed figures, for information only.
Sudeep Pharma Ltd
₹1,008.10
−₹47.10 (−4.46%)
NSE · 15 Oct 2026, close
Market Cap
₹11,863 Cr
CMP
₹1,008.10
52-wk High / Low
₹1,378 / 524
P/E
65.0
P/B
13.4
Book Value
₹78.2
Div Yield
0.14%
ROCE
28.0%
ROE
25.2%
Face Value
₹1
D/E
0.17
Price+30.2% over Max
āagman read
Computed by āagmanPiotroski F-Score
2
/ 9
2 of 9 F-score tests passed
Graham Number
₹164
√(22.5 × EPS × book value per share)
ROIC
15.4%
vs 11.2% sector median
Cash flow to profit
0.40
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
−39
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
22.9%
ROE × earnings retention ratio
ROE stability
5.7
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.00FII +1.38DII −4.05
Latest quarter vs the previous one
Cash-accrual divergence
11.0%
of assets
Low = accruals track cash flow
Strengths
+ROCE has stayed above the sector median for 5 consecutive years (weakest: 28% vs the 2026 sector median of 17%)
+Price trades above its 200-day moving average (1.3x)
Watch-outs
−Annualised volatility of 47.7% is in the high band (≥45%)
−Piotroski F-Score of 2/9 is in the weak band (≤3)
−Balance-sheet accruals of 11.0% of average assets — earnings are not cash-backed
Peer comparison
| Name | P/E | Mar Cap ₹ Cr | ROCE % | ROE % |
|---|
Quarterly results
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 42.3% | 33.6% | 37.3% | 35.2% | 33.7% | 34.9% | 34.6% | 34.8% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS (₹) | 128.13 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 20.3% | 20.5% | 19.5% | 21.0% | 39.9% | 38.2% | 34.7% | 34.5% |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS (₹) | 128.02 | 236.60 | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 | 16.83 |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 | — |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 | — |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 | — |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 | — |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | — |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 | — |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 | — |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 | — |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 | — |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | — |
Cash Flows
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 10 | 35 | −3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity | −22 | −40 | −38 | −50 | −49 | −79 | −327 |
| Cash from Financing Activity | 12 | 13 | 51 | −10 | −13 | 53 | 247 |
| Net Cash Flow | 0 | 8 | 10 | −11 | 4 | 23 | −10 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 36.0 | 36.0 | 33.0 | 49.0 | 36.0 | 28.0 |
| ROE % | — | — | — | — | — | — | 25.2 |
| EPS (₹) | 128.02 | 236.60 | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 |
| Book Value (₹) | — | — | — | — | — | — | 78.2 |
| Face Value (₹) | — | — | — | — | — | — | 1 |
| P/E | — | — | — | — | — | — | 65.0 |
| Div Yield % | — | — | — | — | — | — | 0.14 |
| NPM % | 14.3 | 15.1 | 14.3 | 14.2 | 28.6 | 27.2 | 26.0 |
| OPM % | 21.0 | 20.0 | 20.0 | 21.0 | 40.0 | 38.0 | 35.0 |
| D/E | 0.25 | 0.27 | 0.52 | 0.37 | 0.22 | 0.29 | 0.17 |
| P/B | — | — | — | — | — | — | 13.4 |
Growth
Compounded sales growth
5 years+24.0%
3 years+14.0%
TTM+24.0%
Compounded profit growth
5 years+39.0%
3 years+40.0%
TTM+20.0%
Return on equity
5 years32.0%
3 years32.0%
Last year25.0%
Documents
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Announcement under Regulation 30 (LODR)-Change in ManagementClosure of Trading WindowAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAnnual reports
Annual Report 2026Corporate actions
23 Jul 2026DIVIDENDDividend - Rs 1.50 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman